Parnell has expanded its PropofolVet Multidose product line with a new 50 mL presentation, giving veterinary practices another option for canine anesthesia. The larger format is designed to improve workflow efficiency, optimize inventory management and reduce waste while complementing the company’s existing 20 mL offering.
Newly published research in Parasites & Vectors found that Elanco’s Credelio Quattro demonstrated a faster speed of kill against black-legged ticks than Simparica Trio and NexGard Plus, while maintaining efficacy throughout the monthly dosing interval. The company said the findings support the role of rapid tick control in reducing the risk of tick-borne disease transmission in dogs.
Early data presented at ACVIM Forum 2026 suggest Akston Biosciences’ investigational NGF-targeting Ambifect® candidates provided improvements in canine osteoarthritis pain and function comparable to bedinvetmab (Librela®). The company says the candidates also generated durable anti-NGF immune responses that may support longer dosing intervals pending further clinical evaluation.
Anivive Lifesciences has received full FDA approval for Laverdia (verdinexor), making it the first FDA-approved oral, at-home treatment for canine lymphoma and converting the drug’s previous conditional approval to full approval.
Jaguar Health has submitted a New Animal Drug Application (NADA) to the FDA seeking full approval of Canalevia®-CA1 for chemotherapy-induced diarrhea in dogs, following a pivotal study that met its primary effectiveness endpoint.
A new global survey from Merck Animal Health reveals widespread frustration with canine allergic skin disease, as veterinarians and pet owners report challenges with diagnosis, treatment effectiveness, affordability and long-term compliance.
New preclinical data suggest Akston’s investigational therapy AKS-699 may provide months of itch relief for dogs with atopic dermatitis while requiring significantly fewer treatments than existing anti-IL-31 therapies.
The newly approved vaccine is the first and only 0.5 mL combination vaccine protecting against both Lyme disease and leptospirosis in dogs, reducing the number of injections required during wellness visits.
Rejuvenate Bio has secured $6 million in new funding and launched a strategic R&D collaboration with Merck Animal Health to advance gene therapies targeting chronic and age-related diseases in companion animals.
Federal regulators have issued an Emergency Use Authorization for generic nitenpyram tablets to treat New World screwworm infestations in companion animals, marking the first authorized generic animal drug available for the emerging threat.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.